drugset / Trial / NCT00435279

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

NCT00435279

Phase 3 Completed 678 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).

Timeline

Start
2007-06
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg
Background Venlafaxine Small molecule 75 ug
Background Venlafaxine Small molecule 150 ug